In April, Luis Solera assumes the position of CEO at Barcelona-based biotech Bioiberica. He joins from LIPSA, a leading family business in the oils and fats sector.
https://european-biotechnology.com/wp-content/uploads/2024/04/luis-solera.jpg473420h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2017-04-26 17:05:002017-04-26 17:05:00Bioiberica: A boost to the company
Belgian-Dutch antibody developer Argenx N.V. seeks to raise US$74.7m in a US IPO. The company, which is already listed on Euronext wants to use the proceeds to push development of its autoimmune and cancer drugs.
https://european-biotechnology.com/wp-content/uploads/2024/04/20170424-argenx-nasdaq.jpg6751200Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2017-04-24 15:22:552017-04-24 15:22:55Euronext-listed Argenx plans €68.6m IPO in the US
Four orphan drugs, three biosimilars, and one monoclonal antibody therapy have been recommended for EU market approval by the European Medicines Agency’s CHMP this month.
With treatment cost of €1m+ per patient, Glybera was the most expensive therapy ever approved in Europe. Now, Uniqure has decided to terminate post-marketing studies required for prolongation of its existing EU conditional market approval.
Following the resignation of erstwhile CEO Jim Van heusden, Karolinska Development has promoted Viktor Drvota to the position of head of the company. Drvota held the position of Chief Investment Officer before.
https://european-biotechnology.com/wp-content/uploads/2024/04/viktor-drvota.jpg472420h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2017-04-20 13:38:192017-04-20 13:38:19Karolinska Development: Changes at the top
Autoimmune specialist Galapagos NV (Mechelen, Belgium) has priced its 3,750,000 American Depository Shares (ADSs) in an follow-on offering led by Morgan Stanley at $90 per ADS.
Bioiberica: A boost to the company
AppointmentsIn April, Luis Solera assumes the position of CEO at Barcelona-based biotech Bioiberica. He joins from LIPSA, a leading family business in the oils and fats sector.
Euronext-listed Argenx plans €68.6m IPO in the US
Latest NewsBelgian-Dutch antibody developer Argenx N.V. seeks to raise US$74.7m in a US IPO. The company, which is already listed on Euronext wants to use the proceeds to push development of its autoimmune and cancer drugs.
Longevity: Healthy ageing
BackgroundThe SIDUS® technology platform
ProductsOriginates from the in-depth experience and complete protocol system concerning the manufacture of viral vectors for vaccines or gene therapy.
EMA backs authorisation of biologics
Latest NewsFour orphan drugs, three biosimilars, and one monoclonal antibody therapy have been recommended for EU market approval by the European Medicines Agency’s CHMP this month.
Uniqure withdraws €1m drug Glybera from market
Latest NewsWith treatment cost of €1m+ per patient, Glybera was the most expensive therapy ever approved in Europe. Now, Uniqure has decided to terminate post-marketing studies required for prolongation of its existing EU conditional market approval.
Karolinska Development: Changes at the top
AppointmentsGE partner Synpromics completes financing round
Latest NewsSynthetic promoter and gene expression specialist Synpromics has completed a £5.2m (€6.2m) financing round with existing investors.
e-Therapeutics: Newly in charge
AppointmentsGalapagos raises US$338m
Latest NewsAutoimmune specialist Galapagos NV (Mechelen, Belgium) has priced its 3,750,000 American Depository Shares (ADSs) in an follow-on offering led by Morgan Stanley at $90 per ADS.